Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,866 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,866 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $93.97, for a total transaction of $175,348.02. Following the sale, the chief financial officer now owns 67,542 shares in the company, valued at approximately $6,346,921.74. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total transaction of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.

Natera Price Performance

NASDAQ NTRA opened at $96.98 on Friday. The company’s 50 day simple moving average is $90.56 and its two-hundred day simple moving average is $69.48. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. On average, research analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Piper Sandler upped their price objective on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. The Goldman Sachs Group upped their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Craig Hallum started coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 target price on the stock. Finally, Canaccord Genuity Group boosted their target price on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $86.40.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the business. RiverPark Advisors LLC bought a new position in shares of Natera during the 4th quarter valued at $27,000. Principal Securities Inc. bought a new position in shares of Natera during the 4th quarter valued at $32,000. YHB Investment Advisors Inc. bought a new position in shares of Natera during the 1st quarter valued at $36,000. Harvest Fund Management Co. Ltd bought a new position in shares of Natera during the 3rd quarter valued at $44,000. Finally, Oliver Lagore Vanvalin Investment Group grew its holdings in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.